Thursday, August 15, 2024 Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials A candidate malaria vaccine administered to Malian women prior to pregnancy was safe and provided substantial protection against infection that was sustained over the course of two malaria seasons without the need for a booster dose. Malaria during pregnancy is estimated to cause up to 50,000 maternal deaths and 200,00 stillbirths annually. If confirmed through additional clinical trials, the approach modeled in this NIAID-sponsored study could lead to improved ways to prevent malaria in this vulnerable population. The results were published in Lancet Infectious Diseases. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107